Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMD03 in Relapse and Refractory Pediatric Solid Tumors
NCT06612645Phase 1Recruiting
- Sponsor
- Chulalongkorn University
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B7H3-IL7Ra CAR-T cells in solid tumor, sponsored by Chulalongkorn University. Primary endpoint: Safety and tolerability of B7H3-IL7Ra CAR T cells infusion at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
B7H3-IL7Ra CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06612645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612645.